CD5 and myeloid sarcoma: These mechanisms are consistent with prior studies that have demonstrated CNS persistence of mature B cells [17] and increased numbers of peripheral [18] and CSF [19] CD5+ B cells in MS patients with secondary progressive and active relapsing disease.